ABVX
Abivax SA
$133.90
▲ 1.8%Updated Today 3:42 PM ET
ABVX at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 35/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 1728.0% over the last 12 months
Market Cap
$11.63B
P/E
—
Forward P/E (est.)
—
ROE
-51.7%
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
-2.1%
Debt / Equity
0x
ROIC
-40.0%
Interest Coverage
—
Current Ratio
8.75x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
35/100
Abivax SA (ABVX) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $11.63B.
In its latest reported year it generated about $6.05M in revenue and posted a net loss of $362.99M.
Our model rates ABVX Weak (35/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (5 years of history).
The numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
grew in 2 of the last 4 year-over-year periods
positive in 0 of 5 years
-40.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ABVX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ABVX trades near $133.90, above its 50-day average ($112.92) and 200-day average ($112.34). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 83 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ABVX's is $10.45 (~7.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ABVX found buyers near $74.79 (support) and sellers near $147.98 (resistance); its 52-week range is $7.64–$148.83. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Gross Margin
—
Operating Margin
-4393.9%
Net Margin
-6001.8%
ROE
-51.7%
Abivax SA keeps about n/a of each sales dollar as net profit. Return on equity is -51.7% and return on invested capital about -40.0%. The company is currently unprofitable on a net basis.
Total Debt
$33.25M
Net Debt
-$524.77M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 8.8x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $33.25M of total debt against $558.02M of cash.
Operating CF
-$174.02M
Free Cash Flow
-$174.17M
FCF Margin
-2879.8%
In the latest year Abivax SA produced about -$174.02M of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about -2.1% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
1,019,626x
P/B
19.86x
EV / EBITDA
—
ABVX trades at n/a trailing earnings, 1019626.0x sales, and 19.9x book value. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where ABVX sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How ABVX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), ABVX ranks #69 of 324 by our overall rating.
P/E vs sector
—
median 25.8x
ROE vs sector
-51.7%
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#69
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $133.90 today · expected CAGR -81% – -79%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.53M | $7.05M | $7.62M | $8.23M | $8.89M |
| Net income | $195.96K | $211.63K | $228.56K | $246.85K | $266.59K |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Share price (low) | $0.03 | $0.03 | $0.03 | $0.03 | $0.04 |
| Share price (high) | $0.05 | $0.05 | $0.05 | $0.06 | $0.06 |
| CAGR (low–high) | -100% / -100% | -99% / -98% | -94% / -93% | -87% / -86% | -81% / -79% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ABVX:
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against ABVX:
- Limited free cash flow at today's price.
- Our model's overall read is Weak (35/100).
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Abivax SA is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at n/a earnings, which our model scores Weak (35/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 14 Wall Street analysts covering ABVX recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
ABVX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
ABVX — frequently asked questions
Is ABVX a good stock to buy?
We don't give buy or sell advice. Our model rates Abivax SA Weak (35/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is ABVX's rating on The Stocks School?
Abivax SA currently scores 35/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does ABVX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Abivax SA's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for ABVX calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this ABVX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ABVX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.